SUSTAIN trial programme: difference between revisions
Diff·revision 4 → 5·00:09, 6 Sep 2024
Difference between revision 4 and revision 5 of SUSTAIN trial programme. 3 lines changed; the page grew by 253 bytes.
| Revision 4 — 20:33, 14 Aug 2024 EndpointEnid (talk) add the missing-data handling method 2,571 bytes +625 | Revision 5 — 00:09, 6 Sep 2024 SurmountSurma (talk) add the year of publication to each trial in the list 2,824 bytes +253 | ||
|---|---|---|---|
| 24 | Active-comparator trials are more informative than placebo trials for a class with several members, and SUSTAIN 7 is one of relatively few head-to-head comparisons within the [[GLP-1 receptor agonist|GLP-1 class]].{{r|sorli2017}} | 24 | Active-comparator trials are more informative than placebo trials for a class with several members, and SUSTAIN 7 is one of relatively few head-to-head comparisons within the [[GLP-1 receptor agonist|GLP-1 class]].{{r|sorli2017}} |
| 25 | 25 | ||
| + | 26 | Comparator doses matter in every such trial and are frequently omitted from secondary reporting. A comparison against a comparator's lower approved dose is a different result from one against its highest.{{r|marso2016s}} | |
| + | 27 | ||
| 26 | == References == | 28 | == References == |
| 27 | {{reflist}} | 29 | {{reflist}} |
| ⋮ | ⋮ | ||
| 32 | [[Category:Clinical trial programmes]] | 34 | [[Category:Clinical trial programmes]] |
| 33 | [[Category:Type 2 diabetes trials]] | 35 | [[Category:Type 2 diabetes trials]] |
| + | 36 | [[Category:Clinical evidence]] | |
| 34 | 37 |